Cancer Genetics Revises IPO Filing, Targets $29.3M in Proceeds | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer Genetics plans to raise more than $29 million from its initial public offering, the company said in its amended Form S-1 yesterday.

In the document filed with the US Securities and Exchange Commission, the Rutherford, NJ-based cancer diagnostics firm said it anticipates net proceeds of $29.3 million from the offering. If the underwriters on the offering exercise their over-allotment options in full that figure would increase to $34.2 million.

Aegis Capital and Feltl and Co. are listed as the underwriters on the Form S-1/A.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.